CNTX — Context Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$0.36
-$0.00 (-1.04%)
Context Therapeutics Inc (CNTX) is a biotechnology company listed on NASDAQ. It is led by Martin A. Lehr, based in 2001 Market Street, Philadelphia, PA, United States, 19103, with about 15 employees. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Net income was -$9.7M. CNTX currently screens at market cap $55.1M.
Use this CNTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CNTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CNTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Context Therapeutics Inc even when a live quote feed is slow.
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Key Statistics
Market Cap
$55.13M
Volume
62,755
Previous Close
$0.42
Day Range
$0.42 – $0.44
P/B Ratio
1.16
EPS
-$0.46
Revenue
$0.00
Net Income
-$26.73M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
15
CNTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$26.73M | -$23.96M | -$14.84M | -$10.46M |
| EPS (Diluted) | -$0.46 | -$1.50 | -$0.93 | -$3.69 |
Total Assets
$98.13M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$94.43M
Operating Cash Flow
-$14.56M
Free Cash Flow
$0.00
Context Therapeutics Inc Company Information
- Co-Founder, President, CEO & Director
- Martin A. Lehr
- Headquarters
- 2001 Market Street, Philadelphia, PA, United States, 19103
- Website
- www.contexttherapeutics.com
- Phone
- 267 225 7416
- IPO / Founded
- 2021-10-20
- Sector
- Healthcare
- Industry
- Biotechnology